Half-year 2008 Road Show
|
|
- Ann Banks
- 5 years ago
- Views:
Transcription
1 Half-year 2008 Road Show
2 Disclaimer This presentation contains certain forward-looking statements, which can be identified by use of terminology such as expect, expectation, intend, continue, achieve, maintain, improve, foresee, anticipate, product introductions, outlook, forecast, or similar wording. Such forward-looking statements reflect the current views of management and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause actual results, performance or achievements of the Group to differ materially from those expressed or implied herein. Should such risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this presentation. Straumann is providing the information in this presentation as of this date and does not undertake any obligation to update any forward-looking statements contained in it as a result of new information, future events or otherwise. 2
3 Agenda First-half 2008 highlights Business performance Initiatives to leverage and sustain current growth Outlook Questions & answers 3
4 Straumann sets the pace as first-half net revenue climbs 22% (l.c.) Strong second quarter (+29% l.c.) lifts first-half net revenue to CHF 413 million (+22% in l.c.; +17% in CHF) Gross and EBITDA margins expand as efficiency gains more than compensate for new lower-margin products and unfavorable currency impact Net profit surpasses CHF 100 million to new record level New generation Straumann Bone Level prosthetic range expanded and well received More than 200 new jobs created as Straumann strengthens marketing and sales and other global functions to drive sustainable future growth Straumann on track to meet full-year guidance 4
5 Business performance
6 Accelerated organic growth lifts revenue 22% (l.c.) H net revenue growth in % Total Group: CHF 413 million Organic growth 2 by quarter in % (l.c.) + 4.5% - 5.3% 20% 20% 18% + 0.4% 16% 21.9% 11% 10% 14% 13% 12% 12% 10% 12% 13% 13% 17.4% 16.6% 17.0% Growth CHF Currency effect Growth l.c. Acquisition effect Growth including WL (1) Biora WL effect Organic growth excluding WL Q Q2 Q3 Q4 Q Q2 Organic Organic (excluding Biora US) Organic (adjusted for seasonal factors) 1 WL = FDA Warning Letter effect (US import detention on Biora products) 2 Organic growth excl. FX effects and incl. incremental revenue growth of an acquired business upon consolidation 3 Acquisition effect comprises 6 months of Asian and Czech distributors and 2 months of etkon revenues. 6
7 Consistent strong performances in North America and Europe Regional growth in % Total Group: 22% (l.c.), 17% (CHF) Net revenue by region in % Total Group: CHF 413 million 62% 61% 20% 23% 23% 12% 3% 18% 18% 16% Europe CHF 270m 19% North America CHF 79m 66% Asia/Pacific CHF 51m 3% RoW CHF 13m Europe North America Asia / Pacific RoW CHF l.c. excl. Biora US 1 l.c. 1 No Biora (regenerative) sales in US since early
8 European subsidiaries outperform Market share strengthened as all key countries grow double digit Acquisition of remaining etkon franchise partner (Iberia) completed Bone Level product line launched in all key countries Highly successful ITI meeting in Germany (in CHF million) Q2 07 Q2 08 CHF % H1 07 H1 08 CHF % Net revenue % % Growth in % l.c. +21% +18% +15% +18% 8
9 North America sustains momentum Further acceleration in underlying business despite downturn in the US economy Bone Level Implant and SLActive drive growth as price premium is maintained Continuing weakness of the US dollar constrains Swiss franc growth Import detention on Biora products lifted (in CHF million) Q2 07 Q2 08 CHF % H1 07 H1 08 CHF % Net revenue % % Growth in % l.c. +6% +20% +7% +18% Growth in % l.c. excl. Biora effect +20% +20% 9
10 Asia/Pacific boosted by newly acquired subsidiaries Asian growth lifted by acquired businesses Local management in Japan and South Korea strengthened; upgrade of systems & processes ongoing Continued strong growth in the rest of the world supported by distributor countries, especially China (in CHF million) Q2 07 Q2 08 HY 07 HY 08 APAC net revenue Growth in % CHF. -16% +197% +5% +61% ROW net revenue Growth in % CHF +40% +24% +56% +23% 10
11 Efficiency gains drive gross and EBITDA margins CHF million H H Net revenue growth in % CHF growth in % l.c Cost of goods sold in % of net revenue Gross profit Gross margin in % EBITDA EBITDA margin in % EBITDA margin +40 bps EBIT EBIT margin in % Net profit Net profit margin in % Tax rate 15.5% 11
12 Gross profit margin of underlying business expanded by 100 basis points In % of net revenue - 0.3% + 1.0% - 0.6% COGS: CHF 62.9m 82.1% 81.8% 82.8% COGS: CHF 73.6m 82.2% Gross Profit H12007 (%) FX effect Gross Profit H12007 (%) at FX2008 Productivity improvement (underlying business) Underlying Gross Profit H12008 (%) Acquired businesses (mix effect) Gross Profit H12008 (%) 12
13 EBIT margin constrained by amortization of acquired intangibles and higher R&D investments In % of net revenue - 0.5% + 0.4% - 0.9% - 1.1% + 0.4% 30.7% 30.2% H H EBITDA margin 36.0% 36.4% 29.0% EBIT margin 30.7% 29.0% EBIT margin H12007 Currency effect EBIT margin H12007 at FX2008 Gross profit improvement Intangible amortization (1) Research & SG&A Development improvements (2) EBIT margin H Amortization of intangible assets in connection with recent acquisitions 2 Including other income 13
14 Net profit margin squeezed by higher tax rate (reported) and unfavorable FX developments In CHF million Net profit +6% EBIT CHF +11.9m Finance and Taxes CHF -6.3m Net profit margin 27.0% Net profit margin 24.3% Net profit H Gross profit SG&A R&D costs Other income Financial result Taxes Net profit H
15 Initiatives to leverage and sustain current growth
16 Bone Level prosthetic portfolio expanded: maximum flexibility, minimum complexity Multibase abutment for bridges 140 new prosthetic components added Portfolio covers all indications and preferences but with fewer parts and instruments to maintain simplicity Launch coincides with timing of restoration of first wave of Bone Level Implants placed (time to restoration = longer than with tissue level) and bars 16
17 SLActive in a class of its own with more potential Removal torque Ncm/mm SLActive Main competitor days 3 weeks 6 weeks after implant placement Multicenter study 1-year results 1 show exceptional survival rates, despite >40% of implants being placed in poor quality bone immediate loading = 98% survival early loading = 97% survival bone gain seen with 16% of implants Head to head study 2 shows enhanced osseointegration and secondary stability compared with a main competitor Clinical confirmation of dramatic bone defect filling 3 Well on track to reach penetration target of 30% despite lack of availability in large Asian market 1 Ganeles J et al. Clin Oral Implants Res 2008; (in press) 2 Gottlow J. Preclinical study presented at Toronto Osseointegration Conference Revisited, Schwarz F et al. STARGET 2008;
18 State-of-the-art software extends etkon s competitive position etkon visual 4.3 with new functionality enters prelaunch testing Multiple features enhanced Tooth database enhances design process conventional Undercut feature sets new benchmark in bridge design flexibility Ongoing development with next software release planned for Q etkon 5D 18
19 Regeneratives to benefit from US relaunch and additional application Import detention lifted; Straumann to relaunch regeneratives in US Membrane filed for regulatory clearance, EU, US European Federation of Periodontology Consensus Conference experts develop consensus on Emdogain in the treatment of gum recessions 1, adding to growing attention 2 Before After Treatment supported by Emdogain 1 6th European Workshop on Periodontology, Ittingen, Switzerland, Cheng S et al. J Periodontal Res. 2007; 42:
20 Innovation pipeline to complement ongoing roll-outs and extend the standard of patient care Early development High-strength implant material Advanced development First market introduction Surgical Instruments for guided surgery Tooth-colored implant material Prosthetics and CAD/CAM Customized prosthetic solutions etkon visual software New materials Bars and bridges Regenerative Membrane Bioactive materials 20
21 New high strength implant material with exciting profile First material designed specifically for implant dentistry Surface chemistry & structure + biocompatibility = enhanced osseointegration Remarkable early results point towards a new benchmark in terms of strength combined with osseointegration and safety 1 Pilot study running Multicenter study initiated in 8 centers with 88 patients On track for roll-out in J. Gottlow et al. Preclinical data presented at 23rd Annual meeting of the Academy of Osseointegration (AO), Boston USA 21
22 Production expansion to meet growing demand Implants Extension started in Villeret to increase capacity especially for SLActive production Capacity increased in Andover; further transfer of know-how, including surface treatment CAD/CAM European milling center extension underway in Leipzig North American center expanded 22
23 Building and developing our key asset High caliber professionals attracted from other industries to broaden skills and best-in-class practices New CFO & EVP Operations engaged Considerable investment in upgrading Quality Management 200 new jobs created worldwide in first six months First global employee survey benchmarked to high performance company index 23
24 Outlook
25 2008 guidance confirmed (barring unforeseen circumstances) On the basis of the underlying performance in the first half and the expected contributions from new products, technologies and subsidiaries, Straumann expects 2008 full-year revenue growth to be in the low to mid twenties range in local currencies. As efficiency improvements are expected to exceed the higher levels of amortization related to acquisitions, the Group foresees an improvement of around 50 basis points in full-year operating margin calculated with constant (2008) currency rates. Accounting for the normalized tax rate and the current strength of the Swiss franc, the net profit margin is expected to be around 22%. 25
26 Guidance for 2008 net revenue growth (l.c.) In CHF million + low to mid twenties (%) -38 Currency ØFX 2007 Expected Ø FX 2008 (April) Expected Ø FX 2008 (August) EUR-CHF USD-CHF JPY-CHF GBP-CHF Reported 2007 net revenue Currency impact April August 2007 net revenue at 2008 FXs Expected 2008 net revenue 26
27 Guidance for 2008 operating income margin In CHF million 20 approx. +50 basis points 28 EBIT margin 28.2% EBIT margin 26.9% Reported 2007 EBIT Currency impact 2007 EBIT at FX2008 Expected 2008 EBIT 27
28 Guidance for 2008 net profit margin In CHF million Net profit margin 24.8% Net profit margin 23.4% Net profit margin 21.5% Expected net profit margin around 22% Reported 2007 net profit Currency impact 2007 Net profit at FX 2008 Normalized tax-effect (1) 2007 Net profit adjusted Efficiency gains Expected 2008 net profit 1 One-time tax effect in 2007 (revaluation of deferred tax liabilities) 28
29 Questions & answers
30 Calendar of upcoming events 20 Aug 08 UBS Swiss Summit (Zurich) 02 Sep 08 Sal. Oppenheim European Healthcare Conf. (Frankfurt a.m.) 03 Sep 08 Goldman Sachs European Medtech Conf. (London) 30 Oct 08 Third-quarter and nine-month revenues Feb 09 Full-year results 2008 Detailed calendar on 30
31 Your Investor contacts Head of Investor Relations Fabian Hildbrand Phone +41 (0) Mobile +41 (0) Investor Relations Coordination Bettina Schiendorfer Phone +41 (0)
32 Appendix
33 Accelerated growth across all regions CHF million Q Q Q Q Europe growth in % CHF growth in % l.c North America growth in % CHF growth in % l.c growth in % l.c. excl. Biora Asia / Pacific growth in % CHF Rest of the world growth in % CHF Group growth in % CHF growth in % l.c
34 Straumann's business scope is focused on the fastest growing sectors in dentistry Market sector size* in CHF bn Prosthetics Dental equipment 4 Endodontic 2 Infection control Orthodontic Preventive Restorative 0 Implant dentistry (incl. implants & abutments) Regenerative dentistry CAD/CAM dentistry 0% 5% 10% 15% 20% 25% Market CAGR * Bubble size indicates sector size in CHF bn for 2007 Source: Global Industry Analysts, 2006; Millennium Research Group (MRG) 2008, broker reports 34
35 Straumann is active in three highly attractive dental areas worth together CHF 5bn Implant dentistry market* % = CHF 3.3bn CAD/CAM dentistry market* % = CHF 1.1bn Regenerative dentistry market* % = CHF 0.3bn Others 30% Straumann 17% Straumann <5% Straumann <10% Astra Tech 6% Dentsply 6% Zimmer 7% Biomet/3i 11% Nobel Biocare 23% * DE, IT, ES, FR, SE, UK, CH, US, CA, AU, JP, KR, BR, RU, IN, CN Source: MRG; idata, Straumann estimates 35
36 Markets characterized by low treatment rates Europe North America RoW* Population 380m 330m 410m Prevalence of tooth loss 45-50% 45-50% 60-65% Affected people 180m 155m 265m Annual treatment rate 10-12% 9-11% 6-8% People seeking treatment 20m 15m 21m Exclusion for medical/ other reasons 40-60% 40-60% 40-60% People eligible for impl. treatment 10m 8m 11m Implant treatment rate 12-14% 6-8% 5-7% People treated with implants 1.3m 0.5m 0.8m * Japan, South Korea, Taiwan, Australia and Brazil only Source: Straumann estimates,
37 Our substitution technologies Treatment Manufacturing Materials Crowns and bridges Traditional manufacturing Metals Collagen membranes Dental implants CAD/CAM prosthetics Ceramics Hydrogel membranes 37
38 Key growth drivers Bone Level Implant Roll out progressing well Launch of second wave of prosthetics initiated Preclinical and clinical results SLActive On track to reach penetration target Impressive study findings etkon Roll out progressing well Agreement to acquire remaining franchise partner in Iberia 38
39 Straumann now offers implant solutions to ALL dentists for ALL indications Soft tissue level Bone level New The most successful single system Microgap vertically offset from bone, respecting biological width and preserving bone Preferred solution for one-stage procedures Pioneered by Straumann Most popular implant type globally (70% share in North America) Ease of use and Esthetics considered by many dentists as superior Smart Straumann design limits microgap risk ( platform switching ) 39
40 SLActive cuts healing time by half 1 SLActive SLA Strong hydrophilicity optimized blood-implant contact 2 1 Raghavendra, Wood, Taylor, 2005 and Oates et al., Zhao et al. 2005; Rupp et al
41 Efficiency gain - CAD/CAM prosthetics Tooth preparation (grinding) Impression Taking Restoration (attach Crown or bridge) Finishing (ceramic layer, Centralized production milling centre Make model Scan Model Design restoration Dentist Dental lab & etkon CAD/CAM center 41
42 Worldwide production locations Andover (US): Implant component production Malmö (S): Regenerative products e Leipzig (D): CAD/CAM milling Gräfelfing (D): CAD/CAM milling, scanner production Arlington (US): CAD/CAM milling Villeret (CH): Implant component production 42
43 Straumann offers a comprehensive portfolio Etkon CAD/CAM technology Bone Ceramic Emdogain Prosthetic System Implants SLActive surface 43
44 Straumann a true solution provider with a comprehensive product portfolio BU Surgical New BU Regenerative Scheduled Bone ceramic Membrane Emdogain BU Prosthetics BU Award winning scanners & software Precision production State of the art esthetics 44
45 All significant product needs covered Implants Bone level Tissue level 3rd generation surface Immediate placement Immediate loading Guided surgery Low cost ( ) x Regeneratives BoneCeramic Membrane Periodontal treatment BMPs ( ) (x) Prosthetics CAD/CAM Crown and bridges Ceramics Custom abutments 16-unit bridges Veneers and porcelains x Scanners Software Centralized milling Chairside milling x 45
46 Straumann share price development Stock price development in CHF* July 2002 July CHF Straumann MSCI Healthcare & Equipment Index SPI Swiss Index 50 0 Jul 02 Jul 03 Jul 04 Jul 05 Jul 06 Jul 07 Jul 08 * All indices rebased to Straumann share price Source: Thomson Reuters 46
To be the partner of choice Straumann
To be the partner of choice Straumann Gilbert Achermann, CEO Helvea Swiss Equities Conference 11 January 2008, Bad Ragaz Table of contents 1. A snapshot of Straumann 2. Financials 3. Markets and opportunities
More informationA reliable solution provider. Gilbert Achermann, CEO Sanford Bernstein Strategic Conference 2009
A reliable solution provider Gilbert Achermann, CEO Sanford Bernstein Strategic Conference 2009 Agenda Straumann in brief Future market dynamics Recent market trends Straumann further sustainable growth
More informationStraumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America
Media release Straumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America Group net revenue rises 2% (l.c.) as double-digit increases across America offset
More informationStraumann reports 4% growth in local currencies (l.c.) in the first nine months of 2010
Media release Straumann reports 4% growth in local currencies (l.c.) in the first nine months of 2010 Growth driven by implant volumes, lifted by Bone Level implant range and Roxolid Third quarter (+3%
More informationBeing the partner of choice. Beat Spalinger, CEO & President presenting at the 2011 Berenberg European conference
Being the partner of choice Beat Spalinger, CEO & President presenting at the 2011 Berenberg European conference Disclaimer This presentation contains certain forward-looking statements, which can be identified
More informationBeing the partner of choice
Being the partner of choice Beat Spalinger, President & CEO at the Sanford Bernstein Conference 2012, London Disclaimer This presentation contains certain forward-looking statements, which can be identified
More informationFueling innovation in the premium dental market
Fueling innovation in the premium dental market Francisco Faoro Head Product Development BUSurgical 8 October 2012 Straumann a global leader in replacement, restorative and regenerative dentistry A pioneer
More informationStraumann Group sustains strong performance, as organic revenue rises 18% both in Q3 and over the first nine months of 2018
2018 Nine-months sales report Media Release Straumann Group sustains strong performance, as organic revenue rises 18% both in Q3 and over the first nine months of 2018 Revenue growth in Swiss Francs reaches
More informationStraumann on track with organic 1 growth of 9% in first 9 months
Media release Straumann on track with organic 1 growth of 9% in first 9 months Group revenue climbs 12% in Swiss francs (9% organic, 18% in local currencies) to CHF 585m, including CHF 46m from Neodent
More informationmonths sales presentation Webcast for investors, analysts & media
2016 9-months sales presentation Webcast for investors, analysts & media Basel, 27 October 2016 1 Disclaimer This presentation contains certain forward-looking statements that reflect the current views
More information2017 nine-month & third-quarter sales
2017 nine-month & third-quarter sales Webcast presentation for investors, analysts & media Basel, 26 October 2017 Disclaimer This presentation contains certain forward-looking statements that reflect the
More informationLetter to Shareholders SEMI-ANNUAL REPORT 2008
Letter to Shareholders SEMI-ANNUAL REPORT 2008 Dear Shareholder You have in your hand the first shareholder letter issued by Nobel Biocare. Thanks to the conversion of Nobel Biocare s bearer shares into
More informationStraumann Group raises full-year revenue outlook as organic 1 growth reaches 15% in first nine months
Media Release Straumann Group raises full-year revenue outlook as organic 1 growth reaches 15% in first nine months 9-month revenue climbs 19% in Swiss francs to CHF 801 million Q3 revenue rises 21% in
More informationTaking an important step towards our goal of becoming a total solution provider. International Dental Show (IDS) Cologne, 12 March 2015
Taking an important step towards our goal of becoming a total solution provider International Dental Show (IDS) Cologne, 12 March 2015 1 Today s speakers Marco Gadola, CEO 5 years with the company Dr Gerhard
More informationInterim Report 1, The world leader in innovative evidence-based esthetic dental solutions
Interim Report 1, 2007 The world leader in innovative evidence-based esthetic dental solutions Disclaimer: This presentation contains forward-looking statements that are subject to various risk and uncertainties.
More informationCreating opportunities. Fabian Hildbrand, Investor Relations & Market Research VP Bad Ragaz, 12 January 2017
Creating opportunities Fabian Hildbrand, Investor Relations & Market Research VP Bad Ragaz, 12 January 2017 Disclaimer This presentation contains certain forward-looking statements that reflect the current
More informationThe dental market. Facts, trends and dynamics.
14 Nobel Biocare Annual Report 2013 The dental market The dental market. Facts, trends and dynamics. Facts About 1.7 million licensed dentists worldwide, of which only just over 10% place implants About
More informationProduct Information. Straumann CARES Scan & Shape Turn into digital.
Product Information Turn into digital. I have been using the Scan & Shape service since its introduction by Straumann. I have found it fast, reliable and cost-effective. The ability to preview the case
More informationPersistence Market Research
Persistence Market Research Dental Implants Market is is expected to grow at a CAGR of 9.7% - Persistence Market Research Persistence Market Research 1 Persistence Market Research Released New Market Report
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader
More informationWorldwide Nanotechnology Dental Implants-- Markets Reach $8.1 By 2015
Worldwide Nanotechnology Dental Implants-- Markets Reach $8.1 By 2015 LEXINGTON, Massachusetts (March 14, 2009) WinterGreen Research announces that it has a new study on Worldwide nanotechnology dental
More informationGN Store Nord Goldman Sachs European Medtech and Healthcare Services Conference. CEO GN ReSound, Mike van der Wallen September 3, 2008
GN Store Nord Goldman Sachs European Medtech and Healthcare Services Conference CEO GN ReSound, Mike van der Wallen September 3, 2008 GN Store Nord A/S GN GN Store Store Nord Nord Listed Listed company
More informationFor personal use only
HY18 Result Presentation 13 February 2018 Dig Howitt Brent Cubis CEO & President CFO HY18 Result highlights Strong momentum across developed markets continues Developed market unit growth up 12% Strengthening
More informationTABLE 4 U.S. TEETH CLEANING VISITS BY SELECTED CHARACTERISTICS (%) TABLE 4 (CONTINUED) FIGURE 2 U.S. POPULATION WITH TEETH CLEANING
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 SCOPE OF REPORT... 1 METHODOLOGY... 2 ANALYST... 3 RELATED BCC STUDIES... 3 BCC ONLINE SERVICES... 3 DISCLAIMER...
More informationGlobal Clear Aligner Market: Size, Trends & Forecasts ( ) August 2016
Global Clear Aligner Market: Size, Trends & Forecasts (2016-2020) August 2016 Global Clear Aligner Market Report Scope of the Report The report entitled Global Clear Aligner Market: Size, Trends & Forecasts
More informationGlobal Dental Implant Market Research Report 2018
Report Information More information from: https://www.wiseguyreports.com/reports/3220035-global-dental-implant-market-research-report-2018 Global Dental Implant Market Research Report 2018 Report / Search
More informationSlide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes
Slide 1 International Operations update Mike Doustdar EVP International Operations YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with
More informationProduct Information. Straumann CARES Scan & Shape Turning into digital solutions.
Product Information Turning into digital solutions. I have been using the Scan & Shape service since its introduction by Straumann. I have found it fast, reliable and cost-effective. The ability to preview
More informationGlobal Dental Market Report
Global Dental Market Report ----------------------------------------- Executive Summary The dental market comprises dental consumables and equipment. Dental consumables comprise all materials and consumables
More informationNestlé Investor Seminar 2008
Nestlé Investor Seminar 2008 Nestlé Nutrition update on Acquisitions Richard Laube CEO Nestlé Nutrition 1 Disclaimer This presentation contains forward looking statements which reflect Management s current
More informationSCANNER & SERVICES OVERVIEW
SCANNER & SERVICES OVERVIEW Tim Mack VP BUSINESS DEVELOPMENT & GM ITERO 1 2014 Align Technology, Inc. 1 FORWARD LOOKING STATEMENT During this presentation and corresponding commentary we may make forwardlooking
More informationo Dental Implants Market By Material, Type, Structure Global Forecast To 2022 Report ID: MRDH Publishing Date: July, 2017
o Dental Implants Market By Material, Type, Structure Global Forecast To 2022 Report ID: MRDH-10401 Publishing Date: July, 2017 Sr. No. License Type Price 1 Single User License $4,175.00 2 Multiple User
More informationGlobal Cosmetic Dentistry Market Research Report 2018
Report Information More information from: https://www.wiseguyreports.com/reports/3029111-global-cosmetic-dentistry-market-research-report- 2018 Global Cosmetic Dentistry Market Research Report 2018 Report
More informationColoplast A/S. Investor presentation 1H 2005/06
Coloplast A/S Investor presentation 1H 2005/06 2 Coloplast Coloplast products and services help patients achieve greater independence from medical challenges in 4 areas: Ostomy care, continence care, wound
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationForward Looking Information
Vital Signs, Inc. Forward Looking Information Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned
More informationA GLOBAL LEADER IN PERSONALIZED NUTRITION
A GLOBAL LEADER IN PERSONALIZED NUTRITION Forward Looking Statements Management will make forward-looking statements during this presentation. Actual results could differ from those projected in such forward-looking
More informationCorporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015
(Nasdaq:EVAR) Corporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015 Safe Harbor This presentation contains forward-looking statements as that term is defined in the Private Securities Litigation
More informationUnited for global excellence in dentistry.
United for global excellence in dentistry. TRADITION Rooted in a tradition of legendary Swiss engineering GLOBAL REACH Global reach through subsidiaries and distributors in more than 100 countries INNOVATION
More informationGlobal Invisible Braces Market: Trends, Opportunities and Forecasts ( )
Global Invisible Braces Market: Trends, Opportunities and Forecasts (2016-2021) By Types Clear Aligners, Ceramic, Lingual By Region Americas, Europe, Middle East, Africa, Asia-Pacific By Country- USA,
More informationGoing Digital. Investora Gerhard Mahrle CFO COLTENE Holding AG. September 21, 2017
Investora 2017 Going Digital Gerhard Mahrle CFO COLTENE Holding AG September 21, 2017 COLTENE AN INTERNATIONALLY LEADING DEVELOPER, MANUFACTURER AND SELLER OF CONSUMABLES AND SMALL EQUIPMENT FOR DENTAL
More informationHyundai Motor Company 1 st Quarter 2011 Business Results. April 28, 2011
Hyundai Motor Company 1 st Quarter 2011 Business Results April 28, 2011 Cautionary Statement with Respect to Forward-Looking Statements In the presentation that follows and in related comments by Hyundai
More informationMerrill Lynch conference. Matthew Emmens, CEO Shire plc September 20, 2007
Merrill Lynch conference Matthew Emmens, CEO Shire plc September 20, 2007 THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein that are not historical
More informationIncrease in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014
Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) ( ) H1 2014 revenues and results - 24 July 2014 Forward-looking statement This presentation contains
More informationCreating opportunities for customers and shareholders. Berenberg Equities Conference, Pennyhill, 05 December 2018
Creating opportunities for customers and shareholders Berenberg Equities Conference, Pennyhill, 05 December 2018 Disclaimer This presentation contains certain forward-looking statements that reflect the
More information1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes
1Q 2015 Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes Forward-Looking Statements and Copyright This Presentation includes and is based, inter alia, on forward-looking information and statements
More informationmonths sales presentation Webcast for investors, analysts & media
2015 9-months sales presentation Webcast for investors, analysts & media Basel, 29 October 2015 Disclaimer This presentation contains certain forward-looking statements that reflect the current views of
More informationTelekom Austria Group Results for the 1st Quarter May 27, 2003
Telekom Austria Group Results for the 1st Quarter 2003 May 27, 2003 1 Cautionary Statement This presentation contains certain forward-looking statements. Actual results may differ materially from those
More informationCPH Chemie + Papier Holding AG. Investor Day. Perlen, 13 th September 2018
CPH Chemie + Papier Holding AG Investor Day Perlen, 13 th September 2018 Agenda 2.00 pm Welcome 2.05 pm Presentation Course of Business 2018 2.50 pm Break 3.00 pm Presentation Perlen Packaging 3.30 pm
More informationMarkets Leadership strengthened in a CHF 7 billion market
Management commentary Markets 49 Markets Leadership strengthened in a CHF 7 billion market THE CHF 24BN GLOBAL DENTAL MARKET BY CATEGORY AND IMPLANT SEGMENT SHARE Dental specialties (implants, endodontics,
More informationBank of America Merrill Lynch HealthCare Conference Bayer HealthCare Dr. Jörg Reinhardt. September 14, 2011
Bank of America Merrill Lynch HealthCare Conference Bayer HealthCare Dr. Jörg Reinhardt Chairman of the Board of Management of Bayer HealthCare AG and Chairman of the Bayer HealthCare Executive Committee
More informationNobelProcera Implant Bar Overdenture complete range of fixed and removable solutions.
NobelProcera Implant Bar Overdenture EXPERIENCE THE NEW WORLD OF CAD/CAM DENTISTRY 2 NobelProcera Implant Bar Overdenture NobelProcera Implant Bar Overdenture complete range of fixed and removable solutions.
More informationValue creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO
Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO Forward-looking statements The forward-looking statements contained in this presentation,
More informationPrident SmartSourcing Services: Outsourcing for Today s Cost-Effective Dental Lab
Prident SmartSourcing Services: Outsourcing for Today s Cost-Effective Dental Lab Prident prosthetics.dentsply.com 1-800-618-2431 Prident SmartSourcing Services A Progressive Business Model. What challenges
More informationQ Investor Kit JANUARY-MARCH 2014
Q1 2014 Investor Kit JANUARY-MARCH 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco
More informationJanuary 30, 2018 Dow Wilson President and Chief Executive Officer
Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking
More informationTissue Engineering Market Analysis, Size, Share, Growth, Industry Trends and Forecast to Hexa Research
Tissue Engineering Market Analysis, Size, Share, Growth, Industry Trends and Forecast to 2024 - Hexa Research " The global tissue engineering market was valued to be around USD 23.2 billion in 2015 and
More informationMore than creating smiles. Restoring confidence. Company profile
More than creating smiles. Restoring confidence. Company profile More than creating smiles. Restoring confidence. Straumann is committed to being your global partner of choice for premium tooth replacement
More informationFor personal use only. Investor Briefing. Bayswater, 1 st December 2016
Investor Briefing Bayswater, 1 st December 2016 Introduction Samantha Cheetham Chief Executive Officer To be an innovative leader in the dental industry, developing our people and partnering with dentists
More informationGlobal HPV Vaccine Market: Analysis By End-User (Male, Female), By Age Group (Adolescents, Adults) - By Region, By Country ( )
Global HPV Vaccine Market: Analysis By End-User (Male, Female), By Age Group (Adolescents, Adults) - By Region, By Country (2017-2022) By Region- North America, Europe, APAC and RoW By Country - United
More informationQ Investor Kit January December 2014
Q4 2014 Investor Kit January December 2014 Highlights for Q4 Sales up for all product areas and operating profit from product areas up by 8% Scandinavian hoarding for snus prior to tax increase in January
More informationPatrick J. Sullivan Chief Executive Officer. January 9, 2018 Investor Presentation
Patrick J. Sullivan Chief Executive Officer January 9, 2018 Investor Presentation Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations,
More informationMolecular Diagnostic Solutions for Urologic Cancer
1 Molecular Diagnostic Solutions for Urologic Cancer 2017 First Half Results Presented on 31 August 2017 Dr. Jan Groen, President & CEO Mr. Jean-Marc Roelandt, EVP & CFO 2 Forward looking statement This
More informationColoplast A/S. Investor Presentation 2005/06
Coloplast A/S Investor Presentation 2005/06 2 Coloplast in brief Coloplast s products and services help patients achieve greater independence from medical challenges in 4 areas, ostomy care, urology &
More informationGlobal Dental Implant and Prosthetics Market (By Implant Type, By Prosthetics Type, By Material, By Stage): Opportunities and Forecasts ( )
(By Implant Type, By Prosthetics Type, By Material, By Stage): Opportunities and Forecasts (2016-2021) By Implant Type Endosteal, Subperiosteal, Transosteal; By Material Metals, Ceramics, Polymers, Carbon
More informationJefferies 2014 Global Healthcare Conference November Because people depend on us
Jefferies 2014 Global Healthcare Conference November 2014 Because people depend on us Forward-looking statements This presentation and information communicated verbally to you may contain certain projections
More informationSupplementary Data of Consolidated Financial Statements for the third quarter ended December 31, 2016
Supplementary Data of Financial Statements for the third quarter ended December 31, 2016 January 31, 2017 NITTO DENKO CORPORATION CONTENTS Page Business 1 Segment Information 2 Segment Information By Geographic
More informationDIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM
November 28, 2017 DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM Dr. Jürgen Wunram Agenda Diebold Nixdorf AG History and shareholder structure Market trends, strategy and progress of integration Diebold Nixdorf
More informationSTRAUMANN CARES DIGITAL SOLUTIONS. CARES Implant Prosthetics Ultimate restorative flexibility.
STRAUMANN CARES DIGITAL SOLUTIONS CARES Implant Prosthetics Ultimate restorative flexibility. Customized restorations of exceptional quality from one trusted partner. PERFORMANCE Reached through best-in-class
More informationQ Investor Kit JANUARY-JUNE 2014
Q2 2014 Investor Kit JANUARY-JUNE 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco
More informationVITROLIFE AB (PUBL) Pareto Securities Health Care Conference
VITROLIFE AB (PUBL) Pareto Securities Health Care Conference 2018-09-06 1 2 10 15 % OF ALL COUPLES IN FERTILE AGE SUFFER FROM FERTILITY PROBLEMS LEADING COMPANY IN MEDICAL DEVICES FOR ASSISTED REPRODUCTION
More informationAnnual Shareholders Meeting
Annual Shareholders Meeting February 8, 2018 Dow R. Wilson, President and Chief Executive Officer Forward-Looking Statements Except for historical information, this presentation contains forward-looking
More informationTELECONFERENCE Q August 2015
TELECONFERENCE Q2 2015 19 August 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationPresentation of ALK London, 24 May 2011 UBS GLOBAL SPECIALTY PHARMACEUTICALS CONFERENCE : LONDON : 24 MAY 2011
Presentation of ALK London, 24 May 2011 1 ALK pharma specialist - treatment, prevention and diagnosis of allergies World leader in allergy immunotherapy ~ 33% global market share Expanding Base Business
More informationRoche Diagnostics Daniel O Day COO Roche Diagnostics. Société Générale - The Premium Review Conference, Paris December 2, 2011
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates,
More informationPutting ALK on the right growth trajectory
Putting ALK on the right growth trajectory Økonomisk Ugebrevs Kapitalmarkedseftermiddag 15. marts 2018 Per Plotnikof, VP Corporate Communications and IR Marts 2018 Allergy: a global disease with a large
More informationBeing the partner of choice
Being the partner of choice Investor Breakfast IDS Cologne, 24 March 2011 Straumann: a global leader in replacement, restorative and regenerative dentistry Dental implant systems Regeneratives 2 What are
More informationPresentation of. Burgdorf, 1 st November 2012
Presentation of Semi-Annual Results 2012/13 Burgdorf, 1 st November 2012 Important Notice The information contained in this document has not been independently verified and no representation or warranty,
More informationJanuary 2017 Investor Presentation. confidently live life with ease
January 2017 Investor Presentation confidently live life with ease Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that could
More informationSIMPLANT Guided Surgery delivering restorative-driven implant treatment
SIMPLANT Guided Surgery delivering restorative-driven implant treatment SIMPLANT the key to unlocking digital potential As part of the DENTSPLY Implants Digital Solutions portfolio, SIMPLANT digital implant
More information37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationDELICA D:5 ACTIVE GEAR 0
DELICA D:5 ACTIVE GEAR 0 1 1. FY2017 1Q Results 2. FY2017 1Q Results by Region 3. FY2017 Forecast 4. Initiatives for the Future FY2017 1Q Results Summary (vs. FY2016 1Q) (Apr-Jun 2016) (Apr-Jun 2017) (billion
More informationProduct Information for Labs. etkon ident Perfectly versatile. Performance you can rely on.
Product Information for Labs etkon ident Perfectly versatile. Performance you can rely on. BENEFIT FROM THE BEST OF BOTH WORLDS Versatility Simplicity Industry-leading manu facturing standards Variety
More informationSecond Quarter and First Half 2011 Conference Call. 29 July, SORIN GROUP Presentation 1
Second Quarter and First Half 2011 Conference Call 29 July, 2011 SORIN GROUP Presentation 1 DISCLAIMER This presentation contains management preliminary estimates and forward-looking statements, including
More informationPresentation to 2019 JP Morgan Healthcare Conference
For immediate release 10 January 2019 Presentation to 2019 JP Morgan Healthcare Conference Please find attached CSL Limited s presentation at the 2019 JP Morgan Healthcare Conference. For further information,
More informationLeading Intimate Healthcare. Investor presentation Q1 2007/08
Leading Intimate Healthcare Investor presentation Q1 2007/08 1 2 Agenda Introduction to Coloplast Q1 2007/08 in headlines Outlook for 2007/08 Strategic targets Leading intimate healthcare Appendices Q1
More informationFor personal use only
Cochlear Limited Results for the half year ended 31 December 2011 (H1 F12) Chris Roberts, CEO Neville Mitchell, CFO Cochlear Overview Cochlear Limited (ASX:COH): global leader in implantable devices for
More informationINNOVATION 35 MARKETS
MANAGEMENT COMMENTARY 18 23 27 32 INNOVATION 35 MARKETS 43 49 56 58 60 BUSINESS MODEL & OBJECTIVES STRATEGY IN ACTION PRODUCTS & SERVICES BUSINESS PERFORMANCE GROUP BUSINESS PERFORMANCE REGIONS BUSINESS
More informationMore than pure esthetics. The natural and strong solution.
More than pure esthetics. The natural and strong solution. Expand your patient pool with an innovative solution. With the Straumann PURE Ceramic Implant, clinicians have an additional option to convince
More informationNobelProcera Implant Bar Overdenture EXPERIENCE THE NEW WORLD OF CAD/CAM DENTISTRY
NobelProcera Implant Bar Overdenture EXPERIENCE THE NEW WORLD OF CAD/CAM DENTISTRY 2 NobelProcera Implant Bar Overdenture NobelProcera Implant Bar Overdenture complete range of fixed and removable solutions.
More informationYou design, we create.
CAD/CAM SYSTEMS INSTRUMENTS HYGIENE SYSTEMS TREATMENT CENTRES IMAGING SYSTEMS infinident SIRONA S CENTRAL PRODUCTION You design, we create. www.infinident.gb.com T h e D e n t a l C o m p a n y infinident:
More informationAn exciting combination in a high growth, high margin Nutrition category. Name of chairman
An exciting combination in a high growth, high margin Nutrition category 2 Vevey, December 14, 2006 Disclaimer This presentation contains forward looking statements which reflect Management s current views
More informationKorean Airlines Q Results
Korean Airlines 2010 2Q Results 2010. 8. 13 1 Disclaimer This presentation is for informational purposes only, contains preliminary financial and other information about Korean Air Lines Co., Ltd. and
More informationOperatory Units TABLE 20 SELECT MANUFACTURERS AND DISTRIBUTORS OF DENTAL FURNITURE TABLE 20 (CONTINUED) Cavity Preparation Systems
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 SCOPE AND FORMAT... 1 METHODOLOGY... 1 RELATED BCC STUDIES... 2 ANALYST CREDENTIALS... 2 BCC ON-LINE SERVICES...
More informationH. LUNDBECK A/S. Teleconference. 10 August PM CET. Financial results Second quarter 2011
H. LUNDBECK A/S Teleconference 10 August 2011-2PM CET Financial results Second quarter 2011 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts
More informationTELECONFERENCE Q November 2015
TELECONFERENCE Q3 2015 4 November 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationAustralia Dental Implants And Prosthetics Market By Implant Material (Titanium, Zirconium), Prosthetic Product (Bridges, Crowns, Dentures), Denture
Australia Dental Implants And Prosthetics Market By Implant Material (Titanium, Zirconium), Prosthetic Product (Bridges, Crowns, Dentures), Denture Type (Partial,Complete), and Abutment Type (Definitive,
More informationAcquisition of Novartis Influenza Vaccines Business. 27 th October 2014
1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include
More informationCountry Coverage. Company Coverage
Global Heart Valve Devices Market: Analysis By Procedure (Replacement & Repair), Replacement Procedure By Technique (Mechanical, Bioprosthetic & TAVR), Repair Procedure By Technique (Surgical, Balloon
More information